JP2020512314A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512314A5
JP2020512314A5 JP2019550156A JP2019550156A JP2020512314A5 JP 2020512314 A5 JP2020512314 A5 JP 2020512314A5 JP 2019550156 A JP2019550156 A JP 2019550156A JP 2019550156 A JP2019550156 A JP 2019550156A JP 2020512314 A5 JP2020512314 A5 JP 2020512314A5
Authority
JP
Japan
Prior art keywords
kit according
cancer
antibody
kit
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512314A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/023344 external-priority patent/WO2018183041A1/en
Publication of JP2020512314A publication Critical patent/JP2020512314A/ja
Publication of JP2020512314A5 publication Critical patent/JP2020512314A5/ja
Pending legal-status Critical Current

Links

JP2019550156A 2017-03-27 2018-03-20 サシツズマブゴビテカンとRAD51阻害剤を用いたTrop−2発現トリプルネガティブ乳癌の治療 Pending JP2020512314A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477216P 2017-03-27 2017-03-27
US62/477,216 2017-03-27
PCT/US2018/023344 WO2018183041A1 (en) 2017-03-27 2018-03-20 Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor

Publications (2)

Publication Number Publication Date
JP2020512314A JP2020512314A (ja) 2020-04-23
JP2020512314A5 true JP2020512314A5 (https=) 2021-03-18

Family

ID=63581429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550156A Pending JP2020512314A (ja) 2017-03-27 2018-03-20 サシツズマブゴビテカンとRAD51阻害剤を用いたTrop−2発現トリプルネガティブ乳癌の治療

Country Status (7)

Country Link
US (1) US10918734B2 (https=)
EP (1) EP3600283A4 (https=)
JP (1) JP2020512314A (https=)
CN (1) CN110392570A (https=)
CA (1) CA3050332A1 (https=)
RU (1) RU2758234C2 (https=)
WO (1) WO2018183041A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240139324A1 (en) * 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US20210393617A1 (en) * 2012-12-13 2021-12-23 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (immu-132)
WO2018192407A1 (zh) 2017-04-19 2018-10-25 四川科伦博泰生物医药股份有限公司 细胞毒素和偶联物、其用途和制备方法
CN119241554A (zh) 2017-12-15 2025-01-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN112646038B (zh) * 2019-10-11 2025-06-03 迈威(上海)生物科技股份有限公司 抗人Trop-2抗体及其应用
MX2022010963A (es) * 2020-03-03 2022-12-08 Cyteir Therapeutics Inc El compuesto 67a (2301085-06-1) inhibidor de rad51 en una dosificación específica para el tratamiento de cáncer.
AU2021240037A1 (en) * 2020-03-20 2022-09-22 Immunomedics, Inc. Biomarkers for sacituzumab govitecan therapy
CN113842467A (zh) * 2020-06-28 2021-12-28 达石药业(广东)有限公司 用于抗体与药物偶联体(adc)制备的中间体及其制备方法和应用
CN113171469B (zh) * 2020-10-16 2022-06-14 中山大学孙逸仙纪念医院 靶向肿瘤细胞表面Trop2蛋白的肿瘤治疗纳米药物及其制备方法
CN113117088B (zh) * 2021-02-25 2023-08-08 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用
US20240207432A1 (en) * 2021-04-21 2024-06-27 Biosion Inc. Antibodies binding trop2 and uses thereof
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
EP4408893A4 (en) * 2021-09-29 2026-02-18 Kisoji Biotechnology Inc Binding agents targeting tumor cells expressing too much 2
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ, インコーポレイテッド Cd73化合物
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20240165995A (ko) * 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
CA3256048A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING A TUMOR ANTIGEN
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド Trop-2発現がんを治療するための併用療法
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
WO2024097812A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Therapy for treating bladder cancer
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
FI131754B1 (en) * 2023-03-13 2025-11-11 Glykos Finland Oy Antibody-exatecan conjugates
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
CN116196314B (zh) * 2023-05-04 2023-08-15 广州市妇女儿童医疗中心 Ri-1或其盐在制备防治胃肠道疾病的药物中的应用
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025251025A1 (en) * 2024-05-31 2025-12-04 Gilead Sciences, Inc. Sacituzumab govitecan formulations and methods of manufacture
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4200690A (en) 1976-12-16 1980-04-29 Millipore Corporation Immunoassay with membrane immobilized antibody
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5204095A (en) 1980-04-09 1993-04-20 National Research Development Corporation Monoclonal antibodies against hepatitis B virus
US4359457A (en) 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
US4925922A (en) 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
US4916213A (en) 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4918163A (en) 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
WO1988007553A1 (fr) 1987-03-26 1988-10-06 Teijin Limited Procede de preparation d'un complexe d'anticorps
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5112954A (en) 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8903021D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
JPH02283294A (ja) 1989-04-24 1990-11-20 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
AU7566991A (en) 1990-03-14 1991-10-10 Biomembrane Institute, The Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020075D0 (en) 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
US5679640A (en) 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993021940A1 (en) 1992-05-06 1993-11-11 Immunomedics, Inc. Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
MX9401351A (es) 1993-02-22 1994-08-31 Alza Corp Composiciones para suministro oral para agentes activos.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
IL109666A0 (en) 1993-05-17 1994-08-26 Immunomedics Inc A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US8771694B2 (en) 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5798554A (en) 1995-02-24 1998-08-25 Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno MOS-technology power device integrated structure and manufacturing process thereof
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
EP0954340B1 (en) 1996-05-03 2007-06-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer
JP2000516594A (ja) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
DE19640207A1 (de) 1996-09-30 1998-04-02 Bayer Ag Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3835827B2 (ja) 1997-05-02 2006-10-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ,アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 悪性細胞に対する、oncタンパク質を含む、免疫毒素
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6165440A (en) 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6201104B1 (en) 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6379698B1 (en) 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US20030133972A1 (en) 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
GB0028361D0 (en) 2000-11-21 2001-01-03 Glaxo Group Ltd Method of separating extra chromosomal dna from other cellular components
GB0119665D0 (en) 2001-08-10 2001-10-03 Isis Innovation Conjugates
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
SE0104462D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Peptide purifcation (Peptidrening)
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
FR2840532B1 (fr) 2002-06-11 2005-05-06 Ethypharm Sa Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
CN101972478B (zh) 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US7612153B2 (en) 2004-10-25 2009-11-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) and uses thereof
US8067006B2 (en) 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
JP5232770B2 (ja) 2006-04-19 2013-07-10 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 新規な「反転した」ラクトン安定なe−環を有するカンプトテシン類似体並びにその製造及び使用方法
CA2750038C (en) 2009-02-05 2016-10-04 Oncoxx S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
AU2010295646B2 (en) 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2011155579A1 (ja) 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Trop-2抗体
JP5989668B2 (ja) 2011-01-11 2016-09-07 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント タンパク質検出方法
US9216177B2 (en) * 2011-02-28 2015-12-22 Drexel University Small molecular inhibitors of RAD51 recombinase and methods thereof
WO2012131527A1 (en) 2011-04-01 2012-10-04 Wyeth Llc Antibody-drug conjugates
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原(Trop-2)之專一性抗體類及彼等之用途
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US9492566B2 (en) * 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
WO2015047510A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
JP6980980B2 (ja) * 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗hla‐drまたは抗trop‐2抗体と微小管阻害剤、parp阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド3‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
CN108601841A (zh) * 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性

Similar Documents

Publication Publication Date Title
JP2020512314A5 (https=)
RU2019126562A (ru) ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
JP7608164B2 (ja) 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ
Andrikopoulou et al. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer
A. Baudino Targeted cancer therapy: the next generation of cancer treatment
US20210093730A1 (en) Biomarkers for antibody-drug conjugate monotherapy or combination therapy
Markowska et al. Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer
Walters et al. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer
JP7458981B2 (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2024161445A (ja) 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
JP2018520140A5 (https=)
JP2019535731A5 (https=)
RU2694688C2 (ru) АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2018527383A5 (https=)
JP2020508292A5 (https=)
JP2016503023A5 (https=)
JP2022523740A5 (https=)
RU2019124477A (ru) Терапия мелкоклеточного рака легких (мкрл) с помощью конъюгата антитело-лекарственный препарат (кап), ингибирующего топоизомеразу-i, нацеленного на trop-2
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
JP2021528496A5 (https=)
TW202327652A (zh) 抗trop-2抗體及parp抑制劑之組合療法
Schöffski et al. Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates
JP2007531728A5 (https=)
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物